INTELLIGENT BIO SOLUTIONS INC.
No SEC Form 4 filings for $INBS in the last 30 days.
See all $INBS insider activity →INTELLIGENT BIO SOLUTIONS INC. (INBS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Press Release Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following
Intelligent Bio Solutions Inc. (INBS) reported a wider Q2 net loss of $12.47M, or $8.44 per share, despite a 38% revenue increase to $4.21M. The company plans to submit a FDA 510(k) clearance application by year-end for its drug screening system. INBS stock is down 16.27% to $2.69.
INTELLIGENT BIO SOLUTIONS INC. (INBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over
Over the past 7 days, alphai's AI scored 1 news story mentioning INBS (INTELLIGENT BIO SOLUTIONS INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INBS coverage spans financial news, earnings and corporate actions.
The capital raise provides modest funding but dilutes existing shareholders; limited immediate price impact.
Earnings miss and widening loss pressure share price; FDA filing plan may offer future upside.
Strong top‑line growth and margin expansion suggest improving unit economics and potential upside ahead of FDA submission.
Improves regulatory readiness for FDA clearance efforts, which can be a key gating item for commercialization.
Completion of precision testing is a procedural FDA step that can de-risk the 510(k) package, but it does not confirm clearance or timing.
alphai scores every news story that mentions INBS with an AI model for sentiment and relevance, and aggregates insider trades from INTELLIGENT BIO SOLUTIONS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INTELLIGENT BIO SOLUTIONS INC. (INBS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Press Release Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following
1 min readIntelligent Bio Solutions Inc. (INBS) reported a wider Q2 net loss of $12.47M, or $8.44 per share, despite a 38% revenue increase to $4.21M. The company plans to submit a FDA 510(k) clearance application by year-end for its drug screening system. INBS stock is down 16.27% to $2.69.
2 min readINTELLIGENT BIO SOLUTIONS INC. (INBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over
2 min readBiotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
7 min readIntelligent Bio Solutions (INBS) said it completed precision testing for its Intelligent Fingerprinting Drug Screening System for an FDA 510(k) submission. The company reported reproducible results across 1,600+ tests, three production runs, and three independent sites. The data will be included with other study results in the application, supporting a planned U.S. launch after clearance. INBS stock closed at $1.81, down 8.12%.
3 min readIntelligent Bio Solutions (INBS) announced it has regained compliance with Nasdaq's minimum bid price requirement as of January 7, 2026. This follows its common stock trading below $1.00 for 30 consecutive business days, leading to a deficiency notice in December 2025. The company maintained a closing bid price of at least $1.00 for 14 consecutive business days, removing the immediate delisting risk.
3 min readIntelligent Bio Solutions (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader. This collaboration aims to meet anticipated global demand, support INBS's entry into the US market in 2026, and is expected to achieve over 40% in annual production cost savings while strengthening its supply chain. The partnership leverages Syrma Johari's extensive manufacturing capacity and expertise in medical device production.
3 min readIntelligent Bio Solutions (INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech, aiming to reduce production costs by over 40% and improve gross margins by approximately 20 percentage points. This collaboration quadruples manufacturing capacity in preparation for the planned 2026 U.S. market entry of their fingerprint drug screening reader. The partnership leverages Syrma Johari's extensive global facilities and regulatory certifications to strengthen INBS's supply chain and support future growth.
4 min readIntelligent Bio Solutions Inc (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech, aiming to significantly enhance global production and improve gross margins by 20 percentage points. This collaboration is expected to achieve over 40% annual production cost savings and strengthen INBS's supply chain, supporting its planned U.S. market entry in 2026. Syrma Johari's production capacity is four times INBS's current output.
2 min readIntelligent Bio Solutions Inc. (NASDAQ:INBS) stock dropped 21.3% after announcing a $10 million private placement. The medical technology company will issue nearly 2.3 million shares and warrants to two healthcare-focused institutional investors, with the proceeds intended for working capital and general corporate purposes. This significant decline suggests investor concern over potential share dilution.
3 min read
